Exalenz Bioscience collaborates with Acute Liver Failure Study Group, EndoChoice CFO buys 5k shares & more – 4 GI company key notes

Here are four recent news updates on key gastroenterology and endoscopy companies.

Exalenz Bioscience is collaborating with the Acute Liver Failure Study Group to study the ability of the BreathID Methacetin Breath Test to predict patient outcome in cases of acute liver failure. 

GI Dynamics received the initial results from its pivotal clinical trial of the EndoBarrier therapy.

David N. Gill, CFO of EndoChoice, purchased 5,000 shares of the company in a recent transaction.

Timpani Capital Management raised its stake in Cantel Medical by 1.1 percent.

Intercept Pharmaceuticals developed a new research initiative with the University of Pennsylvania's PennCHOP Microbiome Program to study the effects of obeticholic acid on the microbiome in a number of chronic liver diseases.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast